BioSpace News Archive

Pristine Surgical LLC, makers of the first fully-integrated, single-use visualization platform for rigid endoscopic surgical and diagnostic procedures, announced today that it completed its third round of investment capital raising

Qosina Corp President and CEO Scott Herskovitz today released a statement to customers regarding COVID-19 and the actions the company is taking to handle this unprecedented situation

Adrenomed AG, the vascular integrity company, announces the presentation of topline data from the AdrenOSS-2 Phase II trial in an event hosted today, March 16, 2020, at 5:00 pm CET by the newly established interdisciplinary Sepsis Comprehensive Center Charité (SCCC).

Plan Needed to Treat Dental Emergencies for COVID-19 Patients, Prevent Dental Care from Burdening Hospitals

To assist healthcare organizations in their response to COVID-19, Orbita today announced its new Orbita COVID-19 Virtual Assistant, a turnkey chatbot that can be readily integrated into existing websites to improve access to coronavirus-specific question-answering and screening tools.

Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today reported financial results for 2019 and provided a business update.

Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, today announced that it has raised $45 million in a Series B financing.

EmphyCorp Inc. www.EmphyCorp.com, a Private Corporation, is proud to announce that EmphyCorp Rx N115 Non-Steroidal Nasal Spray with no known side effects for Pulmonary Fibrosis, Cystic Fibrosis, COPD, and Unmet Needs COPD significantly increases patient breathing measurements including FEV-1, SaO2, FVC, FEV-1/FVC ratios and also increases nasal “Nitric Oxide” which is used naturally to kill invading Bacteria, Fungi, and Viruses in the lungs.

Jaeger’s infectious disease expertise provided insights on preventing and managing the spread of disease amongst the homeless and will be key for the population health management industry’s response to COVID-19

Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, announced that it has raised $45 million in a Series B financing.